Directorate Change

Alliance Pharma PLC
06 February 2004

For immediate release:, 6 February 2004





                              ALLIANCE PHARMA PLC

                         ('Alliance' or 'the Company')

                     APPOINTMENT OF NON-EXECUTIVE CHAIRMAN





Alliance Pharma plc, the emerging speciality pharmaceutical company, today
announced that it has appointed Michael Gatenby, aged 59, as non-executive
chairman.



Michael developed a successful career in finance, being a director of Hill
Samuel and Co and Vice Chairman of Charterhouse Bank.  Michael graduated with
Honours in Law from Cambridge in 1966 and qualified as a chartered accountant in
1969.  He is currently a director of Johnson Service Group Plc, Porvair Plc, SRS
Technology Group Plc, Protherics Plc (formerly Proteus International plc) and
Cobra Biomanufacturing Plc.  He is also a Trustee/Director of the Stroke
Association.



Michael Gatenby's previous directorships in the past five years have been with
Bridport plc, SGB Group plc, Powell Duffryn plc as vice chairman and Tarmac plc.



There are no further matters to be disclosed in accordance with paragraph 'f' of
schedule 2 of the AIM rules.



John Dawson, CEO of Alliance Pharma commented:



'It is great news for Alliance that Michael has agreed to join the Board.  He
brings with him extremely strong City credentials as well as considerable
experience in the pharma and biotech areas and he will be able to contribute
enormously to our development.'



                                    - ends -

For further information please contact:

Alliance  Pharmaceuticals Ltd

John Dawson
Managing Director
01249 466966

Beattie Financial
James Chandler/Mike Wort/John Moriarty
020 7398 3300





About Alliance Pharma



Alliance Pharma, founded in 1996, is an AIM listed emerging speciality
pharmaceutical company based in Chippenham, Wiltshire.  The company has a strong
track record of acquiring the rights to established niche brands and owns, or
shares, the rights to 23 branded pharmaceutical products and is currently
exploring several opportunities to expand the range.  In November 2003 the
company acquired Peerless Technology Group Plc constituting a reverse takeover
under the AIM rules.



Alliance's products are prescribed in the treatment of a wide range of
conditions and include brands used in the prevention of heart disease, in
Parkinson's disease, in nasal infections, in the treatment of dermatological
conditions and in childbirth.  Alliance's sales are mainly prescription driven.
They are distributed to hospitals directly and to pharmaceutical wholesalers who
service both hospital and retail pharmacies with their prescription
requirements.


                      This information is provided by RNS
            The company news service from the London Stock Exchange